We provide you with 20 years of free, institutional-grade data for IGMS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IGMS. Explore the full financial landscape of IGMS stock.
| Reported Date | CIK | Ticker | Type |
|---|
IGM Biosciences, Inc(NASDAQ:IGMS) 
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymp...
Website: http://www.igmbio.com
Founded: 1993
Full Time Employees: 103
CEO: Fred M. Schwarzer
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about IGMS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.